Taken together, these results imply that the response to IL-17A is different between PSC and non-PSC ECO at the RNA and protein level, suggesting a role for this signaling pathway in PSC pathogenesis. Here, IL17A is linked to endocrine-cerebro-osteodysplasia syndrome.